Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.
This update enables MAHs to better navigate the requirements for submitting variations, streamlining the process for regulatory compliance in handling veterinary medicinal products.
MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.
Regulatory Intelligence Lead
Review whenever updates to EMA guidance are published.
Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.
Minor procedural update for veterinary MAH regulatory teams handling variations.
MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.
The European Medicines Agency (EMA) has added Question 23 to its Q&A on variations requiring assessment (VRA) for veterinary medicines, involving a minor procedural update for marketing authorisation holders (MAHs) handling such variations.
What changed: Addition of Question 23 to the procedural Q&A regarding variations for veterinary products.
Why it matters: This update enables MAHs to better navigate the requirements for submitting variations, streamlining the process for regulatory compliance in handling veterinary medicinal products.
Practical implication: MAHs are advised to incorporate the updated FAQs into their compliance workflows and ensure that their submissions adhere to the updated guidance.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
